Structure Therapeutics (GPCR) Stock Forecast, Price Target & Predictions
GPCR Stock Forecast
Structure Therapeutics stock forecast is as follows: an average price target of $86.00 (represents a 110.58% upside from GPCR’s last price of $40.84) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
GPCR Price Target
The average price target for Structure Therapeutics (GPCR) is $86.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $65.00. This represents a potential 110.58% upside from GPCR's last price of $40.84.
GPCR Analyst Ratings
According to 5 Wall Street analysts, Structure Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for GPCR stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Structure Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Yasmeen Rahimi | Piper Sandler | $93.00 | $34.72 | 167.86% | 127.72% |
| Aug 09, 2024 | Jonathan Wolleben | JMP Securities | $86.00 | $34.49 | 149.35% | 110.58% |
| Jun 07, 2024 | Evan Seigerman | BMO Capital | $100.00 | $53.07 | 88.43% | 144.86% |
| Apr 09, 2024 | Prakhar Agrawal | Cantor Fitzgerald | $65.00 | $44.41 | 46.36% | 59.16% |
The latest Structure Therapeutics stock forecast, released on Sep 10, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $93.00, which represents a 167.86% increase from the stock price at the time of the forecast ($34.72), and a 127.72% increase from GPCR last price ($40.84).
Structure Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 4 |
| Avg Price Target | $93.00 | $89.50 | $86.00 |
| Last Closing Price | $40.84 | $40.84 | $40.84 |
| Upside/Downside | 127.72% | 119.15% | 110.58% |
In the current month, the average price target of Structure Therapeutics stock is $93.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 127.72% increase as opposed to Structure Therapeutics's last price of $40.84. This month's average price target is up 3.91% compared to last quarter, and up 8.14% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 09, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 07, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Apr 09, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Oct 03, 2023 | BMO Capital | Outperform | Outperform | Hold |
| Feb 28, 2023 | Guggenheim | - | Buy | Initialise |
Structure Therapeutics's last stock rating was published by Piper Sandler on Sep 10, 2024. The company gave GPCR a "Overweight" rating, the same as its previous rate.
Structure Therapeutics Financial Forecast
Structure Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Structure Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GPCR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Structure Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict GPCR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Structure Therapeutics's previous annual EBITDA (undefined) of $NaN.
Structure Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-16.47M | $-14.66M | $-13.84M | $-12.35M | $-11.15M | $-10.09M | $-10.87M |
| High Forecast | $-16.47M | $-14.66M | $-13.84M | $-12.35M | $-11.15M | $-6.56M | $-10.87M |
| Low Forecast | $-16.47M | $-14.66M | $-13.84M | $-12.35M | $-11.15M | $-12.11M | $-10.87M |
| Surprise % | - | - | - | - | - | - | - |
Structure Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GPCR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Structure Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Structure Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GPCR last annual SG&A of $NaN (undefined).
Structure Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.33 | $-0.30 | $-0.28 | $-0.25 | $-0.23 | $-0.20 | $-0.22 |
| High Forecast | $-0.33 | $-0.30 | $-0.28 | $-0.25 | $-0.23 | $-0.13 | $-0.22 |
| Low Forecast | $-0.33 | $-0.30 | $-0.28 | $-0.25 | $-0.23 | $-0.25 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Structure Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GPCR previous annual EPS of $NaN (undefined).
Structure Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| BMEA | Biomea Fusion | $7.85 | $13.67 | 74.14% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| IRON | Disc Medicine | $47.79 | $61.80 | 29.32% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| MORF | Morphic | $56.99 | $57.00 | 0.02% | Hold |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
GPCR Forecast FAQ
Is Structure Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Structure Therapeutics (GPCR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of GPCR's total ratings.
What is GPCR's price target?
Structure Therapeutics (GPCR) average price target is $86 with a range of $65 to $100, implying a 110.58% from its last price of $40.84. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Structure Therapeutics stock go up soon?
According to Wall Street analysts' prediction for GPCR stock, the company can go up by 110.58% (from the last price of $40.84 to the average price target of $86), up by 144.86% based on the highest stock price target, and up by 59.16% based on the lowest stock price target.
Can Structure Therapeutics stock reach $60?
GPCR's average twelve months analyst stock price target of $86 supports the claim that Structure Therapeutics can reach $60 in the near future.
What is Structure Therapeutics's current price target trend?
1 Wall Street analyst forecast a $93 price target for Structure Therapeutics (GPCR) this month, up 127.72% from its last price of $40.84. Compared to the last 3 and 12 months, the average price target increased by 119.15% and increased by 110.58%, respectively.
What are Structure Therapeutics's analysts' financial forecasts?
Structure Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-32.118M (high $-28.585M, low $-34.137M), average SG&A $0 (high $0, low $0), and average EPS is $-0.65 (high $-0.579, low $-0.691). GPCR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-57.319M (high $-57.319M, low $-57.319M), average SG&A $0 (high $0, low $0), and average EPS is $-1.16 (high $-1.16, low $-1.16).